Treating chronic hepatitis C in recovering opiate addicts: yes, we can.
Kreek
M J
MJ
The Laboratory of the Biology of Addictive Diseases, The Rockefeller University, New York, NY, USA. kreek@rockefeller.edu
Talal
A H
AH
Piccolo
P
P
D000998:Antiviral Agents / Q000627:therapeutic use*; D002047:Buprenorphine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D055030:Drug Users; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007558:Italy; D008691:Methadone / Q000627:therapeutic use; D009294:Narcotics / Q000627:therapeutic use*; D010349:Patient Compliance; D011092:Polyethylene Glycols / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D010818:Practice Patterns, Physicians'; D011994:Recombinant Proteins; D016079:Refusal to Treat; D012254:Ribavirin / Q000627:therapeutic use; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000534:rehabilitation*; D016896:Treatment Outcome; D014481:United States
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009294:Narcotics; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D002047:Buprenorphine; D012254:Ribavirin; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a; D008691:Methadone